Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 4, 2000, Pages 1563-1568

  Nordt, T K ^a   Peter, K ^a   Bode, C ^a   Sobel, B E ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; TROGLITAZONE;

AORTA MEDIA; ARTICLE; BLOOD VESSEL WALL; CELL CULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYPERINSULINEMIA; LIVER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

AORTA; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; CHROMANS; CULTURE MEDIA, CONDITIONED; ENDOTHELIUM, VASCULAR; HUMANS; HYPOGLYCEMIC AGENTS; KINETICS; LIVER; LIVER NEOPLASMS; MUSCLE, SMOOTH, VASCULAR; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIAZOLES; THIAZOLIDINEDIONES; TUMOR CELLS, CULTURED; UMBILICAL VEINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0034456123     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.4.1563     Document Type: Article

References (21)

1. Increased plasma plasminogen activator inhibitor 1 levels: A possible link between insulin resistance and atherothrombosis
2. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
3. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo
4. The hemostatic system and coronary heart disease
5. Regulation of the synthesis of plasminogen activator inhibitor type-1 (PAI-1): Pathogenetic mechanism of atherosclerosis in diabetes mellitus?
6. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2
7. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: Implications for vascular disease in hyperinsulinemic states
8. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease
9. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells
10. Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells
11. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
12. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
13. Troglitazone upregulates LDL receptor activity in HepG2 cells
14. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism
15. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs
16. Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors
17. Insulin removal by isolated perfused rat liver
18. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome
19. Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats
20. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells
21. Changes in arterial expression of fibrinolytic system proteins in atherogenesis